Previously recorded as Arcutis, Inc. (to 2021)
35 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jun 2037. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2037
Next term end
9
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2037 · High confidence
Also notable
Ends Dec 2041 · High confidence
Also notable
Ends Sep 2041 · High confidence
Also notable
Ends Dec 2041 · High confidence
Also notable
Ends Jun 2037 · High confidence
Pharmaceutical Compositions of Roflumilast in Aqueous Blends of Water-Miscible, Pharmaceutically Acceptable Solvents
US 11,534,493
Cited by 31 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Topical Roflumilast Formulation Having Antifungal Properties
US 11,707,454
Cited by 15 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2041.
LAURETH-4 Containing Topical Formulations
US 11,730,740
Granted 2023. Computed term ends 2041.
Compositions and Methods for Deep Dermal Drug Delivery
US 11,628,177
Granted 2023. Computed term ends 2041.
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time
US 12,042,558
Granted 2024. Too new for citation comparison; protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Topical Roflumilast Formulation Having Antifungal Properties (US 11,707,454) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due Feb 22, 2027The maintenance fee for LAURETH-4 Containing Topical Formulations (US 11,730,740) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 1 fee due Apr 24, 2027The maintenance fee for Inhibition of Crystal Growth of Roflumilast (US 11,793,796) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 1 fee due May 21, 2027The maintenance fee for Topical Roflumilast Formulation Having Improved Delivery and Plasma Half- Life (US 11,819,496) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
What they patent
The largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Inhibition of Crystal Growth of Roflumilast | 24 in force | to Aug 2037 |
| Compositions and Methods for Deep Dermal Drug Delivery | 2 in force | to Dec 2041 |
| Topical Roflumilast Formulation Having Antifungal Properties | 2 in force | to Dec 2041 |
| LAURETH-4 Containing Topical Formulations | 2 in force | to Sep 2041 |
| Pharmaceutical Compositions of Roflumilast and Solvents Capable of Dissolving High Amounts of the Drug | 1 in force | to Jun 2043 |
| Stable Formulations of SHR0302 | 1 in force | to Dec 2042 |
| Pharmaceutical Compositions of Spironolactone for Deep Dermal Drug Delivery | 1 in force | to Nov 2042 |
| Topical Roflumilast Aerosol Foams | 1 in force | to Aug 2042 |
| Method and Formulation for Improving Roflumilast Skin Penetration Lag Time | 1 in force | to Jun 2037 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,884,050 | Inhibition of Crystal Growth of Roflumilast In force · Medium confidence | In force | Medium confidence | |
| US 9,895,359 | Inhibition of Crystal Growth of Roflumilast In force · High confidence | In force | High confidence | |
| US 9,907,788 | Inhibition of Crystal Growth of Roflumilast In force · High confidence | In force | High confidence | |
| US 10,105,354 | Inhibition of Crystal Growth of Roflumilast In force · Low confidence | In force | Low confidence | |
| US 10,172,841 | Inhibition of Crystal Growth of Roflumilast In force · High confidence | In force | High confidence | |
| US 10,940,142 | Inhibition of Crystal Growth of Roflumilast In force · Low confidence | In force | Low confidence | |
| US 11,534,493 | Pharmaceutical Compositions of Roflumilast in Aqueous Blends of Water-Miscible, Pharmaceutically Acceptable Solvents In force · High confidence | In force | High confidence | |
| US 11,793,796 | Inhibition of Crystal Growth of Roflumilast In force · Low confidence | In force | Low confidence | |
| US 11,819,496 | Topical Roflumilast Formulation Having Improved Delivery and Plasma Half- Life In force · Medium confidence | In force | Medium confidence | |
| US 11,992,480 | Method for Reducing Side Effects from Administration of PHOSPHODIESTERASE-4 Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 35: 20 applications pending · 14 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.